' Unprecedented ' Responses to Neoadjuvant Tx in dMMR Colon Cancer ' Unprecedented ' Responses to Neoadjuvant Tx in dMMR Colon Cancer

An ' innovative ' study of short-course nivolumab plus ipilimumab prior to resection of MMR-deficient colon cancer has achieved ' unprecedented ' pathologic responses, with no recurrences.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news